Refractory Anaemia With Hyperoxalurea

Ehsan, Ayesha; Lone, Ayaz; Sabir, Omer; Tareef, Nauman; Riaz, Shazia; Tanvir, Imrana

doi:10.14302/issn.2574-4488.jna-14-614

Cited by 3 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Все больше данных свидетельствует об изменении микробиома кишечника у пациентов с ХБП: выявлено снижение количества семейств Lactobacillaceae и Prevotellaceae (оба считаются нормальной микробиотой толстой кишки) и в 100 раз больше видов Enterobacteria и Enterococci (которые обычно присутствуют в меньшей пропорции) [23]. Количество аэробных бактерий, в том числе энтерококков и энтеробактерий, было выше у пациентов с хронической почечной недостаточностью (ХПН), чем у здоровых людей [24]. Дисбактериоз кишечника у пациентов с ХБП способствует повышению концентрации уремических токсинов, что, в свою очередь, ведет к прогрессированию ХБП [26,37].…”

Section: микробиота кишечника при хронической болезни почекunclassified

“…Устойчивый к амилазе кукурузный крахмал также может улучшать клиренс креатинина и уменьшить воспаление и почечный фиброз [61]. При лечении синбиотиками в течение 4 недель выявлено снижение общего количества п-крезола в плазме без улучшения желудочно-кишечных симптомов у 30 пациентов с III-IV стадиями ХБП [24,33,37]. Исследование SINERGY показало снижение уровня п-крезилсульфата в сыворотке крови, но не индоксилсульфата, а также благоприятное изменение микробиома стула у 37 пациентов с ХБП IV-V стадии [26].…”

Section: перспективы применения пре-и пробиотиков при заболеваниях почекunclassified

See 1 more Smart Citation

Gut Microbiota - Kidney Axis. Features in Diseases of the Urinary System and Urogenital Tract

Прокопьева¹,

Новикова²,

Khavkin³

2023

Medicine: Theory and Practice

View full text Add to dashboard Cite

В последние годы вызывает повышенный интерес взаимодействие микробиоты кишечника и различных органов, растет количество данных, свидетельствующих о важности оси кишечник почки при почечных заболеваниях. Достижения в области секвенирования кишечного микробиома, связанных метаболитов, определения проницаемости кишечника и воспаления обеспечивают новые терапевтические стратегии, нацеленные на кишечник при заболеваниях почек. In recent years, there has been increased interest in the interaction between the gut microbiota and various organs, and there is growing evidence of the importance of the gut kidney axis in renal disease. Advances in gut microbiome sequencing, associated metabolites, gut permeability, and inflammation provide novel therapeutic strategies targeting the gut in kidney disease.

show abstract

Section: микробиота кишечника при хронической болезни почекunclassified

Section: перспективы применения пре-и пробиотиков при заболеваниях почекunclassified

Gut Microbiota - Kidney Axis. Features in Diseases of the Urinary System and Urogenital Tract

Прокопьева¹,

Новикова²,

Khavkin³

2023

Medicine: Theory and Practice

View full text Add to dashboard Cite

show abstract

“…Fibrogenesis might be involved in the tubulointerstitium resulting in tubulointerstitial fibrosis, glomeruli resulting in glomerulosclerosis or the arterial vasculature resulting in atherosclerotic lesions [5,10]. Various action mechanisms were implicated in renal diseases and renal fibrosis [11][12][13][14][15][16][17][18].…”

Section: Introductionmentioning

confidence: 99%

Action Mechanisms and Therapeutic Targets of Renal Fibrosis

Shang

Zhang

et al. 2018

JNA

View full text Add to dashboard Cite

Renal fibrosis was a chronic and progressive process affecting kidneys in chronic kidney disease (CKD), regardless of cause. Although no effective targeted therapy yet existed to retard renal fibrosis, a number of important recent advances have highlighted the cellular and molecular mechanisms underlying the renal fibrosis. The advances including TGF-β/Smad pathway, oxidative stress and inflammation, hypoxia and gut microbiota-derived from uremic solutes were highlighted that could provide therapeutic targets. New therapeutic targets and strategies that are particularly promising for development of new treatments for patients with CKD were also highlighted.

show abstract

Microbiome–metabolome reveals the contribution of gut–kidney axis on kidney disease

et al. 2019

View full text Add to dashboard Cite

Dysbiosis represents changes in composition and structure of the gut microbiome community (microbiome), which may dictate the physiological phenotype (health or disease). Recent technological advances and efforts in metagenomic and metabolomic analyses have led to a dramatical growth in our understanding of microbiome, but still, the mechanisms underlying gut microbiome–host interactions in healthy or diseased state remain elusive and their elucidation is in infancy. Disruption of the normal gut microbiota may lead to intestinal dysbiosis, intestinal barrier dysfunction, and bacterial translocation. Excessive uremic toxins are produced as a result of gut microbiota alteration, including indoxyl sulphate, p-cresyl sulphate, and trimethylamine-N-oxide, all implicated in the variant processes of kidney diseases development. This review focuses on the pathogenic association between gut microbiota and kidney diseases (the gut–kidney axis), covering CKD, IgA nephropathy, nephrolithiasis, hypertension, acute kidney injury, hemodialysis and peritoneal dialysis in clinic. Targeted interventions including probiotic, prebiotic and symbiotic measures are discussed for their potential of re-establishing symbiosis, and more effective strategies for the treatment of kidney diseases patients are suggested. The novel insights into the dysbiosis of the gut microbiota in kidney diseases are helpful to develop novel therapeutic strategies for preventing or attenuating kidney diseases and complications.

show abstract

Refractory Anaemia With Hyperoxalurea

Cited by 3 publications

References 5 publications

Gut Microbiota - Kidney Axis. Features in Diseases of the Urinary System and Urogenital Tract

Gut Microbiota - Kidney Axis. Features in Diseases of the Urinary System and Urogenital Tract

Action Mechanisms and Therapeutic Targets of Renal Fibrosis

Microbiome–metabolome reveals the contribution of gut–kidney axis on kidney disease

Contact Info

Product

Resources

About